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Mycobacterium tuberculosis (M.tb), the causative bacterium of pulmonary tuberculosis (TB), is a serious global health concern.
Central to M.tb eﬀective immune avoidance is its ability to modulate the early innate inﬂammatory response and prevent
the establishment of adaptive T-cell immunity for nearly three weeks. When compared with other intracellular bacterial lung
pathogens, such as Legionella pneumophila, or even closely related mycobacterial species such as M. smegmatis, this delay is
astonishing. Customarily, the alveolar macrophage (AM) acts as a sentinel, detecting and alerting surrounding cells to the presence
of an invader. However, in the case of M.tb, this may be impaired, thus delaying the recruitment of antigen-presenting cells (APCs)
to the lung. Upon uptake by APC populations, M.tb is able to subvert and delay the processing of antigen, MHC class II loading,
andtheprimingofeﬀectorTcellpopulations.ThisdelayultimatelyresultsinthedeferredrecruitmentofeﬀectorTcellstonotonly
the lung interstitium but also the airway lumen. Therefore, it is of upmost importance to dissect the mechanisms that contribute
to the delayed onset of immune responses following M.tb infection. Such knowledge will help design the most eﬀective vaccination
strategies against pulmonary TB.
1.Introduction:CurrentChallenges
andGlobal Impact
Despite extensive vaccine coverage in endemic areas, pul-
monary tuberculosis (TB) remains one of the top three
infectious causes of death worldwide [1]. With an alarming
9 million new cases annually, it is estimated that one
third of the world’s population is latently infected with
Mycobacterium tuberculosis (M.tb), the causative bacterium
of TB [1]. Following primary infection, greater than 90%
of infected individuals enter into an asymptomatic latency
period, showing no clinical sign of disease (Figure 1). The
ability of the host to control M.tb is accomplished through
bacterial restriction and segregation, rather than clearance.
M.tb, a facultative intracellular pathogen, is spread person-
to-person through infected aerosols generated by coughing
or sneezing. Once deposited in the airways, M.tb primarily
infects the alveolar macrophage, the resident macrophage
of the airway lumen [2, 3]. M.tb has a transmission rate
of 30% or less but the relative susceptibility of an exposed
individual to infection is determined by a number of factors
including the living conditions, contact time with infected
individuals, and immune status [4–7]. It is estimated that
under the correct conditions a single bacillus could establish
a successful infection [2]. The fact that M.tb is spread via
aerosols, and can be infectious in low numbers makes it a
major health concern in regions such as those commonly
seen in developing world with high population densities,
poor living conditions, and immune compromising diseases.
While many infections remain asymptomatic, the sheer
number of infected individuals makes TB the number one
bacterial killer worldwide, responsible for nearly 2 million
deaths annually [1]. The majority of TB-related deaths are
seen in the developing world where infected individuals2 Clinical and Developmental Immunology
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Figure 1: Flow chart of TB disease progression and major events leading to protection. Major steps are outlined for the progression of
and infected or uninfected hosts from the point of exposure to development of active disease or clinical latency (protection). The relative
percentage of individuals to progress between steps is shown beside the appropriate progression line.
cannot aﬀord the lengthy antibiotic regime required to treat
M.tb [1]. Compounding the problem, the only licensed TB
vaccine, Bacillus Calmette-Guerin (BCG), has shown highly
variable eﬃcacy (0–80%) [8]. Even with the highest eﬃcacy,
BCG is only eﬀective in limiting severe disseminated forms
of TB in children, not preventing lung disease or providing
sterile immunity [8]. Moreover, the usefulness of BCG is
further limited as protective immunity typically wanes by
adolescence [9] and cannot be boosted by repeated BCG
vaccination [10]. Further compounding the problem, many
of the regions with the highest incidence of TB also coincide
with those endemic to HIV-AIDS [11]. The ability of HIV-
AIDS to dramatically suppress cellular immunity has made
coinfections with M.tb particularly deadly. Of the estimated
2 million deaths by TB per year, approximately 400,000,
nearly one quarter, are of HIV-TB-coinfected individuals,
highlighting the signiﬁcance of this deadly coinfection [11].
As one of the most persistent global health concerns, the
success of M.tb as a human pathogen can be attributed to
itsabilitytoparasitizethehost-pathogenmicroenvironment.
Studies of ancient DNA and skeletal remaining have traced
the coevolution of M.tb and prehuman lineages for nearly
3m i l l i o ny e a r s[ 12–16]. As such, M.tb has evolved multiple
mechanisms to evade, elude, and subvert the host immune
system. For instance, compared to many other respiratory
pathogens, M.tb infection retards adaptive T-cell activation
by eliciting much delayed T-cell priming and lung recruit-
ment [17, 18]. Temporally, M.tb targets both early immune
initiation as well as chronic bacterial control preventing
the host from ever achieving sterile immunity. While much
research has been done to understand the various ways M.tb
suppresses established immunity, little progress has been
made in understanding the mechanisms underlying delayed
early adaptive immune activation.
To this end, it has been proposed the impairment in
adaptive immune activation may be attributed to a combina-
tion of underlying defects in the immune initiation cascade.
Speciﬁcally, the limited availability of antigen due to the slow
replication rate of M.tbis thought to accountfor a weak early
inﬂammatory response, delaying the recruitment of innate
immune cells into the lung. The impaired entry of immune
cells into the lung coupled with active immune suppression
driven by M.tb are the major mechanisms thought to delay
themigrationofantigen-presentingcells(APC)tothelymph
node. Puzzling and poorly understood, the contributions
of both host and pathogen to the relative delay in T-cell
activation still remain largely unresolved.
2. Initiationof InnateImmunity in
the LungFollowing M.tb Infection
2.1. Infection. M.tb is spread through aerosols generated by
an infected individual [19]. Coughing or sneezing is the
primary method of transmission, and persons with active
disease are highly contagious [11]. Infected aerosols areClinical and Developmental Immunology 3
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Figure 2:Illustrationofthespeculatedmajorimmunologicsetbacksseenintheearlycourseofpulmonary M.tbinfection.Themajordefects
are numbered in the diagram according to the sequence of events. APC: antigen-presenting cells; MLN: mediastinal lymph nodes.
taken into the lung and deposited in the alveolar space,
where M.tb is actively taken up by the resident alveolar
macrophage (AM) via phagocytosis [20]. Once engulfed by
the macrophage, M.tb becomes highly resistant to clear-
ance. This is achieved by evading immune detection and
elimination through a variety of immune evasion strategies,
including blocking phagolysosome fusion and detoxifying
oxygen and nitrogen radicals [21]. Although the primary cell
typetobeinfectedistheAM,M.tbcanalsoactivelyinfectand
replicate within recruited neutrophils [22], dendritic cells
[23], and alveolar type II epithelial cells [24].
2.2. Innate Recognition. Upon entering the airway lumen,
M.tb is thought to “silently” enter the resident AM. Infection
of the AM occurs through receptor-mediated phagocytosis.
Utilizing the complement receptors (CR3 and CR4), the
mannose binding receptor, surfactant molecules, and DC-
SIGN, M.tb rapidly facilitates its uptake by the AM [25–27].
Upon entry, recognition of M.tb is mediated through the
engagement of pattern recognition receptors (PRRs). While
the toll-like receptors (TLRs), speciﬁcally TLR-2, 4, and 9,
have long been recognized as the primary PRRs required
for the detection of M.tb [28, 29] ,r e c e n t l yam e m b e ro ft h e
NOD family of receptors, NOD2, has been shown to play a
critical role in the intracellular recognition and activation by
the M.tb-infected macrophage [30]. Typically, the AM acts
as a sentinel, detecting and alerting surrounding cells to the
presence of an invader. However, in the case of M.tb, this
function is thought to be impaired. In particular, M.tb has
been shown to uniquely engage the mannose receptor (MR)
of responding macrophages. A major cell wall component
of M.tb, lipoarabinomannan (LAM), is alternatively capped
with mannose, which signals through the MR, inducing
an anti-inﬂammatory program; impairing the secretion of
both proinﬂammatory cytokines (TNF-α and IL-1β)a n d
chemokines (MCP-1 & IP-10) [27, 31], thereby deferring the
recruitmentofinnate immune cellstothelung. Interestingly,
M.tb appears to simultaneously induce both pro- and anti-
inﬂammatory eﬀects as it has recently been shown that
M.tb interacts with the airway epithelium to induce the
production of MMP-9, a mechanism to attract macrophages
to the site of infection facilitating its own propagation [32].
2.3. Recruitment of Antigen Presenting Cells (APCs) to the
Lung. The entry of responding immune cells into the lung
involves cell migration across the vascular endothelium and
the airway epithelium that separates the lung interstitium
and airway luminal space. Although not much has been
studied in the context of TB, it is understood that crossing
the endothelium requires appropriate activation, involving
tight junction modiﬁcation and the expression of addressin
molecules on the luminal surface. These processes are
signiﬁcantly inducible by inﬂammatory cytokines such as
TNF-α and IL-1β [33–36]. Preliminary ﬁndings from our
group suggest that there is a minimum recruitment of innate
immune cells to both the lung interstitium and airway
l u m e nf o rﬁ r s t5d a y sp o s t m y c o b a c t e r i a li n f e c t i o n ,w h i c h
is associated with a lack of both TNF and IL-1β induction
in the lung during this time period [unpublished data].
It is thus our belief that the absence of an early innate
inﬂammatory response in the lung represents an important
mechanism delaying the upregulation of chemotactic and
adhesion signals and the subsequent recruitment of innate
immunecellstothelung,whichinturndelaysT-cellpriming
in the draining lymphoid tissues (Figure 2).
2.4.MycobacterialAntigenAcquisition. Undernoninﬂamma-
tory conditions, immune surveillance of the airway lumen
is passive and mediated primarily by a limited number of4 Clinical and Developmental Immunology
intraepithelial dendritic cells (DCs) [37–39]. However, upon
the initiation of an inﬂammatory response, there is a rapid
recruitment of DCs to the various lung compartments [37].
The precise timing of these inﬂammatory events is not fully
understood in the context of M.tb infection. However, as
discussed above, it is believed that the major inﬂux of APCs
into the lung is delayed for the ﬁrst 5–7 days following
infection [40] and the traﬃcking of immune cells from
the vasculature to the airway lumen is a two-step process.
The majority of DCs ﬁrst exit the vasculature into the
interstitium and then migrate through the interstitial matrix
and reach the alveolar epithelium [34, 41]. Rather than
fully entering the airway lumen, the majority of recruited
DCs interdigitate into the epithelial wall, extending their
dendrites into the luminal space where they acquire antigen
or microbial organisms while maintaining access to the
collecting lymphatics located in the interstitium [37, 42].
While TNF has many functions, it is considered central
to the appropriate control of an M.tb infection. During
the initial stages, TNF acts primarily as an alarm cytokine
alertingsurroundingcellstothepresenceofaninfection.Itis
believed that AM-derived TNF commences the recruitment
of innate immune cells by activating the type II alveolar
epithelial cells (AEII). This initiates the production of
chemokines such as MCP-1, upregulates critical adhesion
molecules, and reduces tight junction adhesion [43–45].
Following M.tb infection, it is unclear how the vascular
endothelium becomes activated. However, given their geo-
graphic location and based on the knowledge from other
models, it is plausible that the AEII relay the inﬂammatory
signal from the airway to the interstitium, thereby activating
the endothelium. AEII are central to the initial recruitment
of APCs to the lung, functioning as the “gatekeepers” of
the airway lumen controlling the production of chemokines
such as MCP-1 and regulating the expression of addressin
molecules [38, 46]. The early mobilization of APCs to the
lung is critical to the timely control of an M.tb infection as
it has been shown that in the absence of MCP-1’s receptor,
CCR2, APC recruitment to the lung is signiﬁcantly delayed,
impairing the downstream adaptive immune activation and
bacterial control [47]. Upon entering the lung, it is currently
unknown which subsets of DCs are primarily responsible
for acquiring and transporting antigen or mycobacteria
to the draining lymph node. Further complicating our
understanding, M.tb actively infects macrophage, DC, and
neutrophil populations, all of which have been shown to be
capable of transporting antigen to the MLN [22, 48–50].
3.InitiationofAdaptiveT-CellActivation
inthe MediastinalLymph Node (MLN)
While much controversy surrounds the generation of adap-
tive immune responses following M.tb,i ti sn o ww i d e l y
accepted that the earliest antigen-speciﬁc T-cells are not
observed for at least 10 days postinfection, appearing ﬁrst
in the MLNs [51]( Figure 2). This delay is highly signiﬁcant
when compared to lung infection by other intracellular
pathogens such as inﬂuenza or Legionella pneumophila,
where adaptive responses are seen as early as 2-3 days in
the MLN [52, 53] and in the lung 6-7 days postinfection
[18, 54, 55]. This may suggest that such delay is due to
insuﬃcient bacteria or bacterial products in the lymph
node required for T-cell priming [40]. Much controversy
surrounds the precise arrival of M.tb to the MLN as some
groups have identiﬁed M.tb in the MLN as early as 4hrs
postinfection, while others cannot detect M.tb for 7–9 days
postinfection[40,56].Nevertheless,itisnowwellestablished
that viable M.tb resides within the MLN several days prior
to the emergence of the eﬀector T-cells [23, 40]. We also
detected viable mycobacteria in the MLN within a few days
post-infection[unpublisheddata].AsM.tbisslowgrowing,it
is possible that the antigenic threshold may not be reached in
the MLN until days after mycobacterial arrival. Alternatively,
the delayed T-cell priming could be due to insuﬃcient
APC activation and/or active suppression by M.tb of T-
cell priming. Indeed, considered central to this delay, M.tb
directlyinfectsDCs,impairing both theircapacitytomigrate
to the lymph node and activate na¨ ıve T-cells [23, 57].
3.1. Migration of DCs to the MLN. The ability of antigen-
loaded DCs to home to the MLN is largely due to the
upregulated expression of chemokine receptor CCR7. CCR7
expression allows activated DCs to rapidly migrate towards
the CCL19/21 chemokine gradients generated by the MLN
[39].Khaderetal.[58]havedemonstratedthedependenceof
IL-12p40 for the expression of CCR7 by M.tb-infected DCs.
Tothisend, impairing the productionofIL-12p40 wasfound
to delay the migration of infected DCs to the MLN, thus
deferring T-cell priming by several days [58]. Furthermore,
it has also been demonstrated that M.tb directly induces a
splice variant of the IL-12 receptor, signiﬁcantly enhancing
the responsiveness of infected DCs to IL-12p40, augmenting
the migratory capacity of these populations [59]. It is
proposed that M.tb may utilize the induction of this high
eﬃcacy receptor to facilitate its dissemination away from the
lung in the manner similar to a Trojan horse [59]. These data
suggest that that the delay in T-cell priming is a result of
impairedDCfunctionalityinthelymphnoderatherthanthe
impaired migration of DCs into this compartment [60, 61].
3.2. Migrating APC Subsets. While the intraepithelial DC
may be the primary APC sampling mycobacteria or
mycobacterial antigen in the airway lumen, it has been
proposed that the AM may egress from the airway lumen
into the interstitium, accessing the collecting lymphatics and
transporting M.tb to the MLN [49]. Within the lung, it is
diﬃcult to appropriately classify the APC populations based
on a single cell surface marker. To this end, the expression of
conventional markers such as CD11c must be used in con-
junction with other makers such as MHC class II expression
to denote activated DC populations [39, 62]. In recent years,
therehasbeenamovementtoclassifythemigratorypotential
of speciﬁc DC cell populations in the lung based on cell sur-
face marker expression. While far from resolved, two distinct
DCpopulations havebeenidentiﬁedbasedontheirpotential
to migrate to the MLN. The expression of CD103+ (CD11chiClinical and Developmental Immunology 5
CD11b− MHC-IIhi CD103+) has recently been shown to be
important in transporting apoptotic bodies and mediating
Ag cross-presentation to CD8+ T-cells during many viral
infections[63].TheexpressionofCD11b+(CD11chi CD11bhi
MHC-IIhi CD103−) has been shown to be key to the
delivery of the majority of viable mycobacteria to the MLN
[23]. From our preliminary studies, we have seen a surge
in both DC subsets in the MLN following pulmonary
mycobacterial infection [unpublished data]. As described
above, complement represents one of the major mechanisms
responsible for the uptake of mycobacteria by recruited APC
populations.Assuch,itcanbeconsideredthattheexpression
of both CD11b and CD11c, components of complement
receptors 3 and 4, respectively, may allow for more eﬃcient
uptake of mycobacteria by these APC subsets. An enhanced
capacity to uptake mycobacteria may provide a plausible,
yet unconﬁrmed, explanation for why CD11c+ CD11b+
DCs represent the dominant APC population during M.tb
infection. The relevanceofthese DC populations with regard
to the eﬃciency of antigen presentation and subsequent T-
cell priming is still currently unknown in the context of M.tb
infection. Furthermore, it remains to be understood whether
some of the T-cell-priming APCs in the MLN are actually
AMs, the AMs that have diﬀerentiated into DCs, or M.tb-
loaded neutrophils.
3.3. Passive Transport of M.tb to the MLN. In addition to
the active transport of M.tb/M.tb antigen to the MLN by
migratory DC or AM populations, it has been suggested
that the passive transport of antigen could be accomplished
via the lymphatic drainage of the lung. Whether the M.tb
organism actively utilizes this system to mediate its “cell-
free” dissemination from the lung to the MLN is unknown.
It remains plausible that discrepancy in the time of bacterial
arrival to the MLN and the time of T-cell priming could be
attributed to cell-free transport of M.tb.R e g a r d l e s so fh o w
M.tb arrives in the lymph node, the appropriate activation
of na¨ ıve T-cells depends on the interaction between the
antigen-loaded DCs and their cognate na¨ ıve T-cell. Critical
to this interaction is the expression of suﬃc i e n tl e v e l so f
costimulatory molecules, a high density of MHC loaded
with the cognate antigen, and the production of polarizing
cytokines. The inﬂammatory microenvironment during the
acquisitionofantigenplaysanintegralroleinthematuration
of DC populations and subsequent T-cell priming.
3.4. Mechanisms of Delayed T-Cell Priming. It has long been
recognized that M.tb utilizes the induction of IL-10 as
a means to suppress eﬀector cell function. Speciﬁcally, it
has been demonstrated that infected macrophage and DC
populations can produce high levels of IL-10 in response
to live, but not heat-killed, M.tb [64, 65]. It has been
demonstrated that upon infection, M.tb employs multiple
secreted virulence factors to subvert host recognition, many
of which actively impair antigen processing and loading,
and the surface expression of MHC class II [66–68]. Most
notably, the 19kDa protein secreted by M.tb has been shown
to inhibit the activation of several genes involved in antigen
presentation, including the downregulation of MHC class II,
HLA-DM, and CIITA [66, 67, 69]. In addition to impairing
antigen processing, M.tb’ sm a j o rc e l lw a l lc o m p o n e n t ,c o r d
factor (trehalose 6,6 -dimycolate) has been shown to signiﬁ-
cantlyimpairtheupregulationandappropriateexpressionof
costimulatory molecules such as CD28 [70]. Together, these
impairments are thought to alter or delay T-cell priming
[71]. Furthermore, the expression of high levels of IL-10
results in the preferential induction of an early T regulatory
cellpopulationthatservestodelaytheinitiationofprotective
type 1 immune responses [72].
While virulence has long been considered an underlying
mechanism for the relative delay in T-cell priming, the
evidence from others and us suggests that this delay is
independent of the relative virulence of the mycobacterium
itself, as delayed T-cell priming has also been observed
following infection with attenuated strains of M.tb or
BCG [40, 73]. Rather, it is possible that delayed T-cell
priming is due to factors that are inherent to slow-growing
mycobacterial species. Many species of pathogenic and
nonpathogenic mycobacteria exist in nature. It has been
observed that “pathogenic” mycobacterial spp., such as M.tb,
BCG,andM.avium,replicateslowly,leadtodelayedimmune
activation, and are capable of persistent disease. On the
other hand, “nonpathogenic” mycobacterial spp., such as
M. smegmatis or M. fortuitum, replicate quickly, evoke a
fast T-cell response, and are rapidly cleared [74, 75]. Slow-
growing mycobacteria such as M.tb have developed many
strategies to remain immunologically inert, fundamental to
which are unique modiﬁcations to its cell wall [12, 76].
Compared with nonpathogenic mycobacteria, the capping
of lipoarabinomannan (LAM), a key cell wall component, is
unique. Following further examination, it was revealed that
the cell wall of all pathogenic, slow-growing mycobacteria
contained mannose capped LAM (manLAM). Further, it was
shown that all nonpathogenic, fast-growing mycobacterial
cell walls contained uncapped or phosphor-myo-inositol-
(PI-) capped LAM [75, 77–81]. The mannose capping of
LAM has been shown to facilitate many immunological
events, including phagocytosis by the AM [20], impaired
cytokine and chemokine production [27], delayed phago-
lysosome fusion [82] ,a n ds u p p r e s s e dD Ca c t i v a t i o n[ 83].
It is now commonly accepted that manLAM is highly
immunosuppressive, while uncapped or PI-capped LAM
is strongly immunogenic [75, 80, 84]. While it represents
an interesting postulate, the role that immunesuppressive
manLAM plays in delayed T-cell priming following M.tb
infection remains unknown.
The ability of M.tb to survive in the cell relies heavily on
its unique ability to subvert the innate and adaptive immune
systems. Its unique cell wall structure composed of lipids
and glycoproteins mediates its survival in the phagosome,
primarily through arresting fusion with the lysosome. One
of the major components of the cell wall is mannose-
capped LAM which is thought to be critical to arresting
phagolysosome fusion [85, 86]. The ability of LAM to arrest
phagosome fusion relies on its ability to prevent the phos-
phorylation of phosphatidylinositol 3-phosphate (PI3P), a
required step in the conversion of an early phagosome to6 Clinical and Developmental Immunology
a late phagosome [85]. The ability of LAM to prevent the
phosphorylation of PI3P is mainly attributed to its ability
to prevent the cellular inﬂux of Ca2+,ar e q u i r e ds t e pi n
the activation of phosphatidylinositol kinase (PI3K) [85]. In
addition to LAM, the activation of PI3P is further prevented
by SapM, a secreted PI3P-phosphatase, further ensuring
that the phagosome is arrested at the early stage [85]. In
additiontopreventingphagosomematuration,M.tbencodes
a number of proteins directed at survival in an activated
phagolysosome. The ability to combat reactive nitrogen
intermediates and reactive oxygen species is critical to M.tb’s
survival following the induction of adaptive immunity and
correlates with strain virulence [86, 87]. M.tb encodes two
superoxide dismutases, sodA and sodC, which catalyse the
conversion of superoxide anions to H2O2, and a catalase-
peroxidase katG to combat the increased levels of H2O2 [87].
Furthermore, M.tb encodes a combined NADH-dependent
peroxidase and peroxynitritesreductases which is composed
of four protein components; an alkyhydroperoxidereductase,
a thioredoxin-related oxidoreductase, a dihydrolipoamidea-
cyltransferase, and a lipoamide dehydrogenase [87]. These
four components function to detoxify both RNI and ROS
and protect M.tb from the harsh environment of an activated
phagolysosome,limitingtheavailabilityofM.tbantigen[87].
The ability of M.tb to survive within the APC, coupled
with its slow replication rate, functions to limit the amount
of antigen available to prime required T-cell responses. To
support this notion, we have noted that a 10-fold increase
in the infectious dose of mycobacteria could enhance the
arrival of bacteria to the MLN and accelerate T-cell priming
[unpublished data], indicating that the antigen load in the
lung may be responsible for the delayed T-cell priming seen
in the MLN.
Alterations to the inﬂammatory microenvironment can
signiﬁcantly impair the ability of responding DCs to appro-
priately initiate adaptive immune responses that are central
to the control of M.tb infection. The ability of M.tb to live
intracellularly shields it from the host’s humoral response.
Thus, controlling bacterial dissemination and curtailing its
replication is largely the responsibility of activated T-cells
subsets. Owing to the intracellular and intraphagosomal
nature of M.tb, antigen loading is primarily through the
MHC class II pathway. As such, the dominant T-cell subset
induced is that of a CD4+ IFN-γ+. Additionally, mycobacte-
rial antigen is loaded on the MHC class I pathway by either
cross-presentation mediated by the uptake of apoptotic
bodies or phagosomal escape, allowing for the priming of
antigen-speciﬁc CD8 T-cell [88–91]. Studies using MHC
c l a s sI Ia n dc l a s sId e ﬁ c i e n tm i c eh a v ed e m o n s t r a t e dt h e
relative contribution of CD4 and CD8 T-cells to M.tb
immunity. While a deﬁciency in MHC class I has a limited
impairment on bacterial control, deﬁciency in MHC class
II results in extensive impairment, signifying the relatively
greater importance of CD4 T-cells [90]. Given the central
role of IFN-γ in macrophage activation and nitric oxide
production, a greater impairment is seen in iNOS-deﬁcient
mice then in either MHC class I or II deﬁcient mice, thus
indicating that IFN-γ from both type I CD4 and CD8 T-cells
playsacriticalroleinprotection[90].Whileatype1immune
response eventually ensues, the delayed T-cell priming by
early immune evasion strategies employed by M.tb provides
a critical window for M.tb to grow completely unchecked in
the lung.
4.Effector T-Cell Recruitmentto the Lungs
As expected, delayed T-cell priming in the lymph nodes of
M.tb-infected animals results in delayed arrival of eﬀector T-
cells at the lung, the primary site of infection (Figure 2). This
permits M.tb to increase logarithmically within the lungs of
the host for approximately 20 days, thus establishing a robust
“foothold” prior to the arrival and abundant presence of
antigen-speciﬁc T-cells at the site of infection [92–94]. The
mass arrival of T-cells to the lungs occurring between 18 and
20 days postinfection is associated with the ultimate plateau
of bacterial growth [40, 92, 94, 95].
4.1. Recruitment of T-Cells to the Diﬀerent Lung Compart-
ments. The lung can be divided into two main compart-
ments: the interstitial tissue existing between the alveoli, and
the mucosal surface of the lung known as the airway lumen
(Figure 2). While the timing of T-cell priming in the MLN
ultimately determines the kinetics of eﬀector T-cell migra-
tion to the infected lung, there is growing evidence to suggest
that the coordinated upregulation of several molecules is
essential to the homing of T-cells to the lung. Speciﬁcally,
the most recent focus has been on the kinetics of chemokine
production as well as the coordinated upregulation of
speciﬁc adhesion molecules. Both the expression of integrins
on T-cells and their respective addressin molecules on the
vascular endothelium and alveolar epithelium are essential
to appropriate recruitment of eﬀector T-cells to lung. The
diﬀerential upregulation of these molecules dictates whether
aT - c e l lt r a ﬃcs to the lung interstitium or airway lumen and
can dramatically eﬀect bacterial control. While it is believed
that T-cell traﬃcking to the airway lumen is a required
pr oc essforthec ontr olofM.tb[96],littleworkhasbeendone
to understand the diﬀerential inﬂammatory signals required
to recruit T-cells into the airway lumen. Based on this, most
studies have focused on the molecules required for recruiting
T-cells into the lung as a whole rather than the diﬀerential
lung compartments.
4.2. Critical Chemotactic Molecules. It has been demon-
strated that CCL5 (RANTES) dramatically increases between
day 10 and day 20 post-M.tb infection [97]. However, the
speciﬁc role of this chemokine in T-cell homing to the
lungs has only recently been elucidated. Through the use of
CCL5 knockout (KO) mice, Vesosky et al. [98] have shown
that CCL5 is critically required for the early recruitment of
CCR5-expressing CD4 T-cells to the lung in M.tb-infected
mice. The delay in eﬀector T-cell recruitment in CCL5 KO
mice caused a signiﬁcant reduction in IFN-γ production
andimpairedgranulomaformation,resultinginsigniﬁcantly
higher bacterial burden within the lungs of these animals
when compared to wild type controls [98].Clinical and Developmental Immunology 7
Best known for their critical role in DC homing to
the MLN, CCL19 (MIP-3β), and CCL21 have been recently
shown to be essential in the traﬃcking of IFN-γ+ T-cells
from the MLN to the lungs of M.tb, infected mice. In
the study conducted by Khader [99], CCL19 was shown
to increase in the lungs of infected mice between 15 and
18 days, correlating with the arrival of eﬀector T-cells and
the initiation of granuloma formation. Mice deﬁcient in
CCL19 and 21 showed signiﬁcantly impaired CD4+ IFN-
γ+ T-cell kinetics to the lungs prior to day 30 post-
infection [99]. The blunted T-cell recruitment in the lungs
of CCL19/CCL21-deﬁcient mice resulted in delayed IFN-γ
and iNOS production, macrophage activation, and bacterial
control [99]. This leads to severely impaired granuloma
formation and increased bacterial loads for at least 80 days
postinfection, indicating the critical role of timely T-cell
traﬃcking to the lung [99].
4.3. Adhesion Molecules. In addition to chemokine expres-
sion within the lung, several studies have focused on
identifying the required adhesion molecules and speciﬁc
integrins which mediate the entry of eﬀector T-cells into
the lung. Vascular cell adhesion molecule 1 (VCAM-1)
expression is upregulated in M.tb infected lungs by day 21
and is associated with the recruitment of the majority of
IFN-γ-producing T-cells [100]. The preferential expression
of α4β1 or α4β7 on activated CD4 T-cells makes VCAM-1
essential to eﬃcient recruitment of T-cells into lung [100].
Furthermore, depletion of either α4 or α4β7 results in a
signiﬁcant decrease in the number of lymphocytes within
thelung,theconsequenceofwhichmanifestsingranulocyte-
dominated granulomas consisting of disorganized inﬁltrates
a n dh e i g h t e n e dn e c r o s i s[ 100]. Similar defects in granuloma
formationwereseeninthelungsofmicedeﬁcientCD11a/18,
where a 3-4 fold reduction in the number of antigen-speciﬁc
T-cells recruited resulted in increased neutrophilia, necrotic
foci, and poorly formed granulomas [101]. It is therefore
apparent that the timing of eﬀector T-cell traﬃcking into the
lungs following M.tb infection is critical to the establishment
of granuloma formation as well as appropriate bacterial
control.
5. Effector Functions of Recruited
T-Cells in the Lung
Upon arrival in the lung, eﬀector T-cells are thought to
mediate protection by two primary mechanisms: (1) the
activation of infected macrophages to produce antimicrobial
substances, and (2) the physical segregation of infected
cells to granuloma structures. While in 90% of infected
humans these methods allow for the host to control M.tb
dissemination and achieve latency, rarely is the bacteria
cleared.
5.1. Macrophage Activation. The airway lumen is largely
considered the primary site of infection. With eﬀector T-
cellsbeingrecruitedtotheairwaylumen,T-cell-derivedIFN-
γ activates infected AMs to mediate enhanced phagosome
lysosome maturation, upregulation of MHC class II loading,
and the induction of highly toxic antimicrobial substances.
The increase in MHC class II expression allows infected
macrophages to be targeted by Th1 CD4 T-cells, and either
activated to kill internalized bacteria or removed by Fas/FasL
or TNF-directed apoptosis [2, 102–105]. Following IFN-γ
mediated activation, the infected macrophage generates both
reactive oxygen substances (ROSs) and reactive nitrogen
intermediates (RNIs) [106, 107]. Although the generation
of ROS, such as H2O2, has been demonstrated following
M.tb infection, it is believed that the major mediator of
antimycobacterial action is through the generation of RNI,
speciﬁcally nitric oxide (NO) by the inducible nitric oxide
system iNOS-NOS2 [106, 107] .L i m i t e dr e s i s t a n c et oR N I si s
a common feature of mycobacteria, with the most virulent
strains such as M.tb and M.bovis being almost completely
resistant [106, 107]. Although sterile clearance is never
achieved, the activation of an infected macrophages is
thought to be strongly bacteriostatic, facilitating the persis-
tence of M.tb within the host [107]. The key role of IFN-
γ in this process is without question and was conclusively
shown with murine IFN-γ-deﬁciency models [108]. In the
absence of IFN-γ, mice fail to upregulate NOS2 and are
unable to control bacterial dissemination, succumbing to
the infection within the ﬁrst few weeks [108]. Despite the
unprecedented role of IFN-γ, it cannot function alone. IL-
12 was shown to be essential to the optimal induction of
both NO and TNF [109]. Other studies have demonstrated
an essential role for TNF and it is now believed that IL-12,
IFN-γ, and TNF must be present for optimal NO production
[103, 105].
5.2. Granuloma Formation. The induction of what is termed
the “immune” granuloma is the hallmark of immune
mediated control and is thought to represent the primary
mechanism of long-term protection. The formation of the
“immune” granuloma is a very operose process, which
follows the arrival of the adaptive immune cells to the
lung, an event not normally seen until 2-3 weeks postin-
fection as aforementioned [60]. The “immune” granuloma
induces a number of deﬁned histopathological changes to
the innate granuloma structure. The innate granuloma is
further fortiﬁed by the arrival of eﬀector T-cells, and the
ability of infected macrophages to kill internalized bacteria
is enhanced by the release of IFN-γ [99]. The addition
of eﬀector T-cells to the granuloma produces what is
termed the lymphocytic cuﬀ, where entering lymphocytes
surround the infected macrophage populations forming
a barrier, adjoining with the focal infection [2, 89, 104,
110–112]. The formation of the lymphocytic cuﬀ and the
ensuing production of inﬂammatory mediators results in
deﬁned structural changes to the partitioned macrophage
populations. Two major morphological changes occur in the
infected macrophage populations, within the type I granu-
loma: ﬁrst, the induction of an epithelial-like appearance,
producing epithelioid macrophages, and second, the fusion
ofmacrophagepopulations toformmultinucleatedgiantcell
populations [2, 89, 104, 110–112]. The arrival of eﬀector8 Clinical and Developmental Immunology
T-cells and the formation of an “immune” granuloma
correlateswiththecessationofbacterialgrowthandaplateau
is reached [2, 89, 104, 110–112]. Type 1 cytokines including
IL-12, IFNγ,a n dT N F α required for macrophage activation
are also essential to granuloma formation [113] or the
maintenance of granuloma [114].
5.3. Granuloma as a Symbiotic Microenvironment for My-
cobacterial Persistence. Recently, many groups have begun
to compartmentalize the granuloma away from the lung
parenchyma and airway lumen. Mounting evidence from
us and others suggests that the granuloma represents an
immunologically suppressed or dampened zone that the
mycobacterium prefers to dwell in [115–117]. The immuno-
logical suppression of the granuloma was determined to be
due to high levels of IL-10, which functioned to suppress
both APC and T-cell populations within the granuloma
[116]. Granuloma-derived IL-10 suppresses many eﬀector
functions of the resident APC populations. Within the
granuloma, APCs show an impaired ability to phagocytose
mycobacteria, drive T-cell priming, and produce nitric
oxide [116]. Granuloma resident T-cell populations are also
phenotypically distinct, having a regulatory-like function
and producing high levels of IL-10 and low levels of IFN-γ
[116]. Removing IL-10 from the model was shown to reverse
the suppression on the APC and T-cell populations in the
granuloma and overall better bacterial control was achieved
[116]. Thus, the renewed knowledge of mycobacterial gran-
uloma biology helps us further understand why the host
immune system can hardly eliminate infection and often the
latency is the best outcome.
6. Role of AirwayLuminalT-Cells
(ALTs) inAnti-TBImmunity
Primary mycobacterial infection studies have demonstrated
that the delayed eﬀector response in the lung is a direct result
of retarded T-cell priming in the MLN. As described above,
the lung can be divided into two main compartments: the
interstitial tissue residing in between the alveoli, and the
mucosal surface of the lung known as the airway lumen.
Although the current literature describes the kinetics of
eﬀector T-cell responses in the whole lung, the role of
ALTs in the airway lumen have been largely neglected to
date [96, 118]. Recently, our group and others have begun
to characterize the T-cell kinetics in these two lung tissue
compartments. Despite the earlier arrival of eﬀector T-cells
in the lung interstitium, following M.tb infection, it is the
arrival of ALTs to the airway lumen that is associated with
the plateau of bacteria replication [119], (Figure 2). Inspired
by the plethora of TB vaccine studies understanding the
role of T-cells in the diﬀerential lung compartments, this is
the ﬁrst study to characterize the T-cell responses in both
the lung interstitium and airway lumen following a primary
challenge.
6.1. Mucosal versus Parenteral Vaccination Against M.tb .
Over the past decade, the development of novel TB vaccine
candidates has produced a wealth of knowledge on the ways
inwhichTBvaccinationcanbeimproved.Arguablythemost
signiﬁcant ﬁnding has been the repeated observation that
vaccinating mucosally provides enhanced protection over
parenteral immunization against pulmonary M.tb infection.
In particular, work from our laboratory has demonstrated
thatarecombinantadenoviralvectorexpressingM.tbantigen
85a (AdAg85a) when delivered intranasally was seen to pro-
vide remarkably enhanced protection against virulent M.tb
challenge compared to intramuscular administration [120].
Furthermore, intranasal vaccination was able to provide
superior protection over the “Gold Standard” subcutaneous
BCG immunization, with at least an additional log reduction
in bacterial burden following M.tb infection [120]. However,
the AdAg85a work does not stand alone, as several others
have reported that mucosal immunization provides greater
protection against M.tb infection compared to parenteral
vaccination [121, 122].
6.2. Requirement of ALTs. Investigation into the mechanism
by which this enhanced protection is achieved revealed
that mucosal but not parental vaccination with AdAg85a
resulted in the generation of a population of antigen-speciﬁc
T-cells that reside within the airway lumen [123]. The
failure of parenteral vaccination to generate a population
of ALTs can be largely attributed to the lack of an inﬂam-
matory response generated in the airway [123]. This defect
is particularly evident in experiments where the delivery
of soluble mycobacterial antigens to the airway elicits a
potent inﬂammatory response characterized by heightened
levels of TNF, MIP-1α, MCP-1, and IP-10 [124, 125]. The
production of these inﬂammatory mediators functions to
draw in peripherally primed T-cells, enhancing protection to
a level comparable to that of mucosally vaccinated animals
[124, 125]. The neutralization of IP-10 or MIP-1α at the
time of soluble protein delivery signiﬁcantly impaired the
recruitment of peripherally primed T-cells into the airway,
impairing protection, thereby demonstrating the critical
role of these chemokines in populating this compartment
[124, 125]. Speciﬁcally, ALTs were found to be critical for
protection as they are capable of responding quickly upon
M.tb infection, eliminating the delay of eﬀector responses
[124, 125]. These ﬁndings indicate that both the timing
and geographic localization of T-cell responses is critical to
the eﬃciency of bacterial control. Following primary M.tb
infection, it is essential to understand the role that the
various immune molecules play in the recruitment of T-cells
both to the lung interstitium, and most importantly to the
airway lumen. Such knowledge will provide further insight
intothemechanismsofdelayedorimpairedT-celltraﬃcking
to the lung, and thus provide ways by which protection
against M.tb can be enhanced.
7. Concluding Remarks
Understanding the mechanisms of delayed T-cell priming in
the MLN and delayed eﬀector T-cell recruitment to the lung
interstitium and airway lumen following pulmonary M.tbClinical and Developmental Immunology 9
infection is critical for us to develop eﬀective anti-TB vaccine
and therapeutic strategies. The current vaccine initiatives are
signiﬁcantly hampered by our limited knowledge of what a
protective immune correlate looks like as following infection
M.tb is rarely cleared. Although much progress has been
made in understanding the kinetics of T-cell priming fol-
lowing M.tb, the mechanisms underlying this delay are only
beginning to be understood. Given the intimate relationship
betweenthehostandbacteria,itisofparamountimportance
for us to further dissect the diﬀerential contributions of
both the host and pathogen to the relative delay in T-cell
priming and recruitment, and their impact on bacterial
control.
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